Managing cardiovascular risk in patients with chronic inflammatory diseases

被引:0
作者
Boulos Haraoui
Peter P. Liu
Kim A. Papp
机构
[1] CHUM,Rheumatology
[2] Hôpital Notre-Dame,Peter Munk Cardiac Centre
[3] University Health Network,undefined
[4] Probity Medical Research,undefined
来源
Clinical Rheumatology | 2012年 / 31卷
关键词
Cardiovascular disease; Inflammatory diseases; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis;
D O I
暂无
中图分类号
学科分类号
摘要
The role of traditional risk factors in the development of cardiovascular disease has been well studied. However, the relationship between chronic inflammatory conditions and cardiovascular risk has only recently been appreciated. Expression of numerous pro-inflammatory cytokines is common to the pathogenesis of both atherosclerosis and other chronic inflammatory diseases and may suggest that systemic inflammation independently contributes to elevated risk. This article examines the magnitude of cardiovascular risk in several of the most common chronic inflammatory diseases and summarizes currently available data to discern whether this risk is largely due to the presence of co-existing traditional risk factors for cardiovascular disease or the effect of increased systemic inflammation. Evidence is summarized to show which therapies may positively or negatively impact cardiovascular risk. Evidence is discussed in context of practical patient management tools, appropriate treatment based on risk, and treatment targets for high-risk patients. Overall, patients with chronic inflammatory diseases are at an often underestimated increase in cardiovascular risk and require individualized therapy and specific patient management strategies to address the disease process, cardiovascular risk factors, and comorbidities.
引用
收藏
页码:585 / 594
页数:9
相关论文
共 177 条
[1]  
Redberg RF(2009)ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovas
[2]  
Benjamin EJ(2009)2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations Can J Cardiol 25 567-579
[3]  
Bittner V(2006)Prevalence of cardiovascular risk factors in patients with psoriasis J Am Acad Dermatol 55 829-835
[4]  
Genest J(2009)Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality Arch Dermatol 145 700-703
[5]  
McPherson R(2003)Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis Circulation 107 1303-1307
[6]  
Frohlich J(2008)Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation Rheumatology (Oxford) 47 718-723
[7]  
Neimann AL(2003)Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis J Rheumatol 30 36-40
[8]  
Shin DB(2005)Inflammation, atherosclerosis, and coronary artery disease N Engl J Med 352 1685-1695
[9]  
Wang X(2002)Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study Arterioscler Thromb Vasc Biol 22 1662-1667
[10]  
Margolis DJ(2009)Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study Arterioscler Thromb Vasc Biol 29 1702-1708